文献速递淋巴瘤

阿基仑赛一线治疗高危大B细胞淋巴瘤的三年随访分析:ZUMA-12研究

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.
PubMed 文献 · Blood · 2025-01-01

ZUMA-12是一项多中心2期研究,评估阿基仑赛(axi-cel)自体抗CD19嵌合抗原受体(CAR)T细胞疗法作为高危大B细胞淋巴瘤(LBCL)一线治疗的一部分。在40例接受治疗的患者中,中位随访47.0个月后,可评估患者的完全缓解率升至86%,36个月总生存率为81.1%,未发现新的安全性信号,提示其可能为高危LBCL的有效一线治愈性疗法,但尚需进一步评估其对比标准治疗的获益。

要点

  • 可评估患者完全缓解率86%,客观缓解率92%。
  • 36个月无事件生存率73.0%,总生存率81.1%。
  • 4例新发恶性肿瘤,均与axi-cel无关。

核心结论

  • 长期随访后,阿基仑赛显示出高持久缓解率,主要分析后未出现新的安全性信号,提示其可能为高危LBCL的有效一线治愈性疗法;尚需进一步评估其对比标准治疗的获益。

研究设计与样本

  • ZUMA-12为多中心2期研究,评估阿基仑赛自体抗CD19 CAR T细胞疗法作为高危LBCL一线治疗的一部分,共40例接受治疗患者,随访≥3年。
  • 符合条件的成人接受白细胞分离、淋巴细胞清除化疗和阿基仑赛输注(2×10^6 CAR T细胞/kg)。
  • 评估研究者评估的完全缓解、客观缓解、生存、安全性和CAR T细胞扩增。

主要发现

  • 可评估患者(n=37)完全缓解率在主要分析后升至86%(95%CI 71%-95%),客观缓解率92%。
  • 中位随访47.0个月(范围37.1-57.8个月)时,36个月缓解持续时间估计为81.8%(95%CI 63.9%-91.4%),无事件生存率73.0%(95%CI 55.6%-84.4%),无进展生存率75.1%(95%CI 57.5%-86.2%),总生存率81.1%(95%CI 64.4%-90.5%)。
  • 共4例患者出现新发恶性肿瘤,其中2例发生在主要分析数据截止后;均与阿基仑赛无关。
  • 8例患者在研究中死亡,其中2例死于非复发死亡原因。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 尚需进一步评估以确定其对比标准治疗的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ZUMA-12 is a multicenter phase 2 study evaluating axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy as part of first-line treatment for high-risk large B-cell lymphoma (LBCL). In the primary efficacy analysis (n = 37; median follow-up, 15.9 months), axi-cel demonstrated a high rate of complete responses (CR; 78%) and a safety profile consistent with prior experience. Here, we assessed updated outcomes from ZUMA-12 in 40 treated patients after ≥3 years of follow-up. Eligible adults underwent leukapheresis, lymphodepleting chemotherapy, and axi-cel infusion (2 × 106 CAR T cells/kg). Investigator-assessed CR, objective response, survival, safety, and CAR T-cell expansion were assessed. The CR rate among response-evaluable patients (n = 37) increased after the primary analysis to 86% (95% confidence interval [CI], 71%-95%), with a 92% objective response rate. After a median follow-up of 47.0 months (range, 37.1-57.8 months), 36-month estimates (95% CI) of duration of response and event-free, progression-free, and overall survival were 81.8% (63.9%-91.4%), 73.0% (55.6%-84.4%), 75.1% (57.5%-86.2%), and 81.1% (64.4%-90.5%), respectively. In total, 4 patients had new malignancies, 2 occurring after the data cutoff of the primary analysis; none were axi-cel-related. Eight patients died on study, 2 of whom died from nonrelapse mortality causes. After long-term follow-up, axi-cel demonstrated a high durable response rate, with no new safety signals after the primary analysis, suggestive of an effective first-line therapy with curative intent in high-risk LBCL. Further assessments are needed to determine its benefit vs standard of care. This trial was registered at clinicaltrials.gov, as NCT03761056.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chavez JC, Dickinson M, Munoz J, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025. PMID: 39938019. doi:10.1182/blood.2024027347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。